

# Matthew A Spinelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/654904/publications.pdf>

Version: 2024-02-01

50  
papers

2,163  
citations

257357

24  
h-index

254106

43  
g-index

55  
all docs

55  
docs citations

55  
times ranked

2908  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pragmatic randomized trial of a pre-visit intervention to improve the quality of telemedicine visits for vulnerable patients living with HIV. <i>Journal of Telemedicine and Telecare</i> , 2023, 29, 187-195.	1.4	7
2	Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 455-462.	0.5	13
3	Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e916-e919.	2.9	42
4	Impact of Multicomponent Support Strategies on Human Immunodeficiency Virus Virologic Suppression Rates During Coronavirus Disease 2019: An Interrupted Time Series Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, e947-e954.	2.9	4
5	Promises and challenges: cabotegravir for preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 186-191.	1.5	7
6	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab640.	0.4	56
7	Characterizing the COVID-19 Illness Experience to Inform the Study of Post-acute Sequelae and Recovery. <i>International Journal of Behavioral Medicine</i> , 2022, 29, 610-623.	0.8	9
8	Relationship Dynamics are Associated with Self-Reported Adherence but not an Objective Adherence Measure in Malawi. <i>AIDS and Behavior</i> , 2022, 26, 3551-3562.	1.4	2
9	Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection. <i>Clinical Infectious Diseases</i> , 2021, 72, 486-489.	2.9	12
10	Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2021, 72, 2025-2028.	2.9	4
11	Sensitivity and Specificity of the National Death Index for Multiple Causes of Death in People With HIV. <i>Public Health Reports</i> , 2021, 136, 595-602.	1.3	5
12	Tenofovir-based PrEP for COVID-19: an untapped opportunity?. <i>Aids</i> , 2021, 35, 1509-1511.	1.0	9
13	Disparities in Integrase Inhibitor Usage in the Modern HIV Treatment Era: A Population-Based Study in a US City. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab139.	0.4	1
14	Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART. <i>Drug Testing and Analysis</i> , 2021, 13, 1354-1370.	1.6	4
15	Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab200.	0.4	9
16	SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. <i>Lancet HIV</i> , 2021, 8, e334-e341.	2.1	99
17	Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases – Authors' reply. <i>Lancet Infectious Diseases</i> , 2021, 21, 915-916.	4.6	2
18	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. <i>Science Advances</i> , 2021, 7, .	4.7	117

#	ARTICLE	IF	CITATIONS
19	Effectiveness of Adding a Mask Recommendation to Other Public Health Measures. <i>Annals of Internal Medicine</i> , 2021, 174, 1193-1193.	2.0	0
20	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. <i>Cell Reports</i> , 2021, 36, 109518.	2.9	142
21	SARS-CoV-2 vaccination in people with HIV. <i>Lancet HIV</i> , 2021, 8, e455-e456.	2.1	6
22	Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 57-60.	0.9	3
23	SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV. <i>Aids</i> , 2021, 35, 2545-2547.	1.0	14
24	Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity. <i>Lancet Infectious Diseases</i> , 2021, 21, e296-e301.	4.6	57
25	The interplay between HIV and COVID-19: summary of the data and responses to date. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 63-73.	1.5	131
26	Pre-exposure Prophylaxis Persistence Is a Critical Issue in PrEP Implementation. <i>Clinical Infectious Diseases</i> , 2020, 71, 583-585.	2.9	29
27	Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings. <i>Aids</i> , 2020, 34, 255-260.	1.0	38
28	Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19. <i>Aids</i> , 2020, 34, 2328-2331.	1.0	76
29	Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 149-152.	0.9	11
30	The importance of PrEP persistence in preventing HIV infections on PrEP. <i>Journal of the International AIDS Society</i> , 2020, 23, e25578.	1.2	4
31	Understanding PrEP Persistence: Provider and Patient Perspectives. <i>AIDS and Behavior</i> , 2020, 24, 2509-2519.	1.4	48
32	Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States. <i>Journal of the International AIDS Society</i> , 2020, 23, e25472.	1.2	40
33	Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. <i>Current HIV/AIDS Reports</i> , 2020, 17, 301-314.	1.1	83
34	Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15029.	0.5	14
35	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 788-793.	0.5	8
36	Missed Visits Associated With Future Preexposure Prophylaxis (PrEP) Discontinuation Among PrEP Users in a Municipal Primary Care Health Network. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz101.	0.4	49

#	ARTICLE	IF	CITATIONS
37	Addressing the Sexually Transmitted Infection and HIV Syndemic. JAMA - Journal of the American Medical Association, 2019, 321, 1356.	3.8	22
38	Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 72-77.	0.9	50
39	Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics. Aids, 2019, 33, 2189-2195.	1.0	55
40	High Interest in Doxycycline for Sexually Transmitted Infection Postexposure Prophylaxis in a Multicity Survey of Men Who Have Sex With Men Using a Social Networking Application. Sexually Transmitted Diseases, 2019, 46, e32-e34.	0.8	19
41	Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 158-162.	0.9	16
42	Homelessness at diagnosis is associated with death among people with HIV in a population-based study of a US city. Aids, 2019, 33, 1789-1794.	1.0	26
43	Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project. Aids, 2019, 33, 867-872.	1.0	29
44	Brief Report: A Panel Management and Patient Navigation Intervention Is Associated With Earlier PrEP Initiation in a Safety-Net Primary Care Health System. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 347-351.	0.9	31
45	Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence. EClinicalMedicine, 2018, 2-3, 22-28.	3.2	42
46	Provider Adherence to Pre-exposure Prophylaxis Monitoring Guidelines in a Large Primary Care Network. Open Forum Infectious Diseases, 2018, 5, ofy099.	0.4	26
47	Factors Associated with Substance use in Older Homeless Adults: Results from the HOPE HOME Study. Substance Abuse, 2017, 38, 88-94.	1.1	43
48	Food Insecurity is Associated with Poor HIV Outcomes Among Women in the United States. AIDS and Behavior, 2017, 21, 3473-3477.	1.4	32
49	Predominant Mode of Human Immunodeficiency Virus Transfer between T Cells Is Mediated by Sustained Env-Dependent Neutralization-Resistant Virological Synapses. Journal of Virology, 2007, 81, 12582-12595.	1.5	394
50	Common Tasks in Microscopic and Ultrastructural Image Analysis Using ImageJ. Ultrastructural Pathology, 2007, 31, 401-407.	0.4	192